May 2010
BioWorld Today;5/11/2010, Vol. 21 Issue 90, p2
This section offers news briefs on clinical trials including the completion by Generex Biotechnology Corp. of enrollment of patients in its Phase III trial of Generex Oral-lyn and the encouraging pharmacokinetic results obtained by QRxPharma Inc. from its trial of a controlled-release dual-opioid.


Related Articles

  • Generex wins approval for impaired glucose tolerance study.  // PharmaWatch: Biotechnology;Sep2008, Vol. 7 Issue 9, p13 

    The article reports that the ethics committee of the University Campus Bio-Medico of Rome has approved Generex Biotechnology Corp. to conduct a trial for its oral insulin spray Generex Oral-lyn in Italy. The trial aims to determine whether Generex Oral-lyn reduces the glucose levels of patients...

  • GENEREX GETS APPROVAL FOR ORAL-LYN PHASE III TRIAL.  // Worldwide Biotech;Mar2008, Vol. 20 Issue 3, p4 

    The article reports on the approval given by Ukraine's Ministry of Health to Generex Biotechnology Corporation for the conduct of a Phase III clinical trial for Generex Oral-lynâ„¢ at several clinical sites in the country. Generex has plans to conduct trials in seven countries. Type-1...

  • Prostate Cancer Update.  // PharmaWatch: Cancer;Sep2006, Vol. 5 Issue 9, p11 

    The article reports global developments related to prostate cancer. Aeterna Zentaris Inc.'s investigational anticancer drug ozarelix has produced positive trial. Biomira Inc. has released study results showing that Stimuvax could slow rising prostate specific antigen levels in some post-surgical...

  • Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials. Boggs, Jennifer // BioWorld Today;4/3/2008, Vol. 19 Issue 65, p3 

    This article reports on the money being raised by Generex Biotechnology Corp. to support the late-stage trials of Oral-lyn, an insulin spray product for Type I and Type II diabetes patients. Eight percent of convertible notes and warrants will be issued by Generex Biotechnology to existing...

  • CLINIC ROUNDUP.  // BioWorld Today;11/6/2007, Vol. 18 Issue 216, p8 

    This section presents news briefs on the biotechnology industry. Emergent BioSolutions Inc. has completed a human study to support the expansion of BioThrax, anthrax vaccine absorbed, in post-exposure prophylaxis in people exposed to anthrax. Epeius Biotechnologies Corp. has opened a Phase II...

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • CLINIC ROUNDUP.  // BioWorld Today;6/6/2008, Vol. 19 Issue 110, p7 

    This section offers news briefs on the biotechnology market. Cytokinetics Inc. has announced data from its Phase I/II trial evaluating its drug candidate SB-743921 in the treatment of patients with Hodgkin or non-Hodgkin lymphoma. Emergent BioSolutions Inc. has started dosing of patients in a...

  • CLINIC ROUNDUP.  // BioWorld Today;9/17/2008, Vol. 19 Issue 181, p4 

    This section offers news briefs on clinical trials in the biopharmaceutical industry as of September 17, 2008. A milestone has been reached by Generex Biotechnology Corp. with the enrollment for its pivotal Phase III trial of Generex Oral-lynn. Safety analysis data from a Phase III trial of...

  • Clinic Roundup.  // BioWorld Today;9/14/2012, Vol. 23 Issue 179, p5 

    This section offers news briefs on the pharmaceutical industry. Biodel Inc. started a Phase II trial of its recombinant insulin-based ultra-rapid-acting mealtime insulin candidate, BIOD-123. Generex Biotechnology Corp. has released early results from a Phase II study of its AE37 vaccine in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics